| Graham Mooy, MD | |
|
2400 N Washington Blvd, Noth Ogden, UT 84414-7233 | |
| (801) 442-3059 | |
| Not Available |
| Full Name | Graham Mooy |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 2400 N Washington Blvd, Noth Ogden, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063703668 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 15271 (Nevada) | Secondary |
| 207P00000X | Emergency Medicine | 9454073-1205 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
The Jenex Corporation, a medical device company focused on the development and application of products based on its patented thermal therapy technology, today announced that on December 1, 2009 it closed a brokered private-placement equity financing. The offering is subject to receiving final acceptance from The TSX Venture Exchange.
Biomarkers, which allow diseases to be diagnosed and staged based on relatively non-invasive blood tests, have been identified for several types of cancers, but for most cancers remain elusive. Now, research conducted at the RIKEN Center for Life Science Technologies in Japan and the Harry Perkins Institute of Medical Research in Australia has identified a large number of genes that are upregulated in many different types of cancer, opening the door for developing biomarker tests that could be used to detect cancers early, allowing for prompt treatment.
DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the third quarter of 2010: $1.8 million revenue, $11.4 million backlog, and continued profitability, resulting in a cash increase over second quarter 2010.
AIM Health Group Inc., a fully integrated health care company, announced today that its net income for the year ended December 31, 2009 ("Fiscal 2009") increased to $1.3 million from a loss of $2.9 million in 2008. At the same time EBITDA increased to $3.0 million from negative $0.3 million on a year-over-year basis.
The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.
› Verified 4 days ago
| Entity Name | Emergency Physicians Integrated Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578598199 PECOS PAC ID: 4284548116 Enrollment ID: O20031115000013 |
News Archive
The Jenex Corporation, a medical device company focused on the development and application of products based on its patented thermal therapy technology, today announced that on December 1, 2009 it closed a brokered private-placement equity financing. The offering is subject to receiving final acceptance from The TSX Venture Exchange.
Biomarkers, which allow diseases to be diagnosed and staged based on relatively non-invasive blood tests, have been identified for several types of cancers, but for most cancers remain elusive. Now, research conducted at the RIKEN Center for Life Science Technologies in Japan and the Harry Perkins Institute of Medical Research in Australia has identified a large number of genes that are upregulated in many different types of cancer, opening the door for developing biomarker tests that could be used to detect cancers early, allowing for prompt treatment.
DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the third quarter of 2010: $1.8 million revenue, $11.4 million backlog, and continued profitability, resulting in a cash increase over second quarter 2010.
AIM Health Group Inc., a fully integrated health care company, announced today that its net income for the year ended December 31, 2009 ("Fiscal 2009") increased to $1.3 million from a loss of $2.9 million in 2008. At the same time EBITDA increased to $3.0 million from negative $0.3 million on a year-over-year basis.
The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.
› Verified 4 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
The Jenex Corporation, a medical device company focused on the development and application of products based on its patented thermal therapy technology, today announced that on December 1, 2009 it closed a brokered private-placement equity financing. The offering is subject to receiving final acceptance from The TSX Venture Exchange.
Biomarkers, which allow diseases to be diagnosed and staged based on relatively non-invasive blood tests, have been identified for several types of cancers, but for most cancers remain elusive. Now, research conducted at the RIKEN Center for Life Science Technologies in Japan and the Harry Perkins Institute of Medical Research in Australia has identified a large number of genes that are upregulated in many different types of cancer, opening the door for developing biomarker tests that could be used to detect cancers early, allowing for prompt treatment.
DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the third quarter of 2010: $1.8 million revenue, $11.4 million backlog, and continued profitability, resulting in a cash increase over second quarter 2010.
AIM Health Group Inc., a fully integrated health care company, announced today that its net income for the year ended December 31, 2009 ("Fiscal 2009") increased to $1.3 million from a loss of $2.9 million in 2008. At the same time EBITDA increased to $3.0 million from negative $0.3 million on a year-over-year basis.
The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Graham Mooy, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (801) 442-3059 | Graham Mooy, MD 2400 N Washington Blvd, Noth Ogden, UT 84414-7233 Ph: (801) 442-3059 |
News Archive
The Jenex Corporation, a medical device company focused on the development and application of products based on its patented thermal therapy technology, today announced that on December 1, 2009 it closed a brokered private-placement equity financing. The offering is subject to receiving final acceptance from The TSX Venture Exchange.
Biomarkers, which allow diseases to be diagnosed and staged based on relatively non-invasive blood tests, have been identified for several types of cancers, but for most cancers remain elusive. Now, research conducted at the RIKEN Center for Life Science Technologies in Japan and the Harry Perkins Institute of Medical Research in Australia has identified a large number of genes that are upregulated in many different types of cancer, opening the door for developing biomarker tests that could be used to detect cancers early, allowing for prompt treatment.
DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the third quarter of 2010: $1.8 million revenue, $11.4 million backlog, and continued profitability, resulting in a cash increase over second quarter 2010.
AIM Health Group Inc., a fully integrated health care company, announced today that its net income for the year ended December 31, 2009 ("Fiscal 2009") increased to $1.3 million from a loss of $2.9 million in 2008. At the same time EBITDA increased to $3.0 million from negative $0.3 million on a year-over-year basis.
The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.
› Verified 4 days ago